PHILADELPHIA--(BUSINESS WIRE)--TransCelerate BioPharma Inc., and BioCelerate announce that its new technology platform, DataCelerateTM, is live and accessible to participating TransCelerate and BioCelerate Member Companies. The global platform allows for multiple de-identified research and development data types to be submitted, uploaded, converted, harmonized, and downloaded through an access controlled, secured environment.
Mike Graziano, PhD, Vice President at Bristol-Myers Squibb and leader of the BioCelerate Toxicology Data Sharing Initiative states, “We’ve built DataCelerate to provide Member Companies with the opportunity to make more informed decisions around product development, further validate key study findings and diminish attrition earlier. It was designed to scale various types of data and has the potential to connect with other external existing data sources, reducing the many data silos that exist today.”
The robust development and scalable design of DataCelerate features a flexible single sign-on platform with an automated user interface to quickly develop translational insights across the research and development (R&D) continuum. The technology can support both structured and unstructured data and is built on the Accenture Insights Platform (AIP) by Accenture Applied Intelligence to provide dynamic search, analytics, visualization and reporting.
“TransCelerate and BioCelerate Members envisioned a solution that would enable collaboration and sharing of R&D data,” notes Dalvir Gill, PhD, CEO of TransCelerate BioPharma, Inc. “We see the value of this system only growing as we increase data volume, expand data types and over time provide the ability for these disparate forms of data to connect within disease areas or drug classes.”
Dr. Gill also shared, “With a future vision of linking de-identified, clean and converted data across the entire R&D continuum, the innate flexibility and modularity of the underlying data lake will serve as a foundation for future TransCelerate clinical data and preclinical contributions, expediting the discovery of translational insights and predictive outcomes in order to bring new medicines to patients faster.”
Currently, the first data set - preclinical toxicology data - is live and accessible in DataCelerate. TransCelerate’s Placebo and Standard of Care (PSoC) data repository will be migrated into DataCelerate, expanding the volume of data to include over 85,000 patients and in excess of 130 studies in nearly 20 therapeutic areas ranging from diabetes to rare conditions such as Duchenne muscular dystrophy.
Elliott Levy, MD, Senior Vice President, Global Development at Amgen and Chair of the TransCelerate Board of Directors commented on the DataCelerate launch, “A number of TransCelerate Member Companies have already experienced great benefit from having access to de-identified historical clinical trial control data from other companies. We’ve been able to improve our clinical trial designs, and better understand incoming safety data. As more sponsors embrace data sharing, we have the potential to significantly reduce randomization to placebo and standard of care arms.” He went on, “DataCelerate offers the potential for better predictive science and reduced patient exposure to placebo. It is also a major step toward a more sophisticated data sharing process for all R&D stakeholders.”
DataCelerate is currently only available to TransCelerate and BioCelerate Member Companies. To inquire about joining these organizations, please contact email@example.com or refer to our Membership Application.
About TransCelerate BioPharma, Inc.
TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating the research and development (R&D) of innovative new therapies. The organizations' mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design, and facilitate implementation of solutions designed to drive the efficient, effective, and high-quality delivery of new medicines. The vast majority of TransCelerate solutions are publicly available. The Member Companies of TransCelerate are AbbVie, Allergan, Inc., Amgen, Inc., Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Novartis, Novo Nordisk, Pfizer, the Roche Group, Sanofi, Shionogi & Co., Ltd. and UCB.
Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research & Development operations. Executive offices are located in Philadelphia, PA. For more information, please visit http://www.transceleratebiopharmainc.com.
BioCelerate explores areas in preclinical research that have unmet needs that could benefit from a collaborative approach. Initiatives are approved by a governing council made up of participating BioCelerate Member Companies. BioCelerate is a separate legal subsidiary of TransCelerate BioPharma with separate funding and support. The organization is led by TransCelerate CEO, Dalvir Gill. To participate in BioCelerate, you must be a Member Company of TransCelerate BioPharma, Inc. For more information, please visit http://www.transceleratebiopharmainc.com/biocelerate.
Follow us on Twitter: https://twitter.com/transcelerate
Reach us on LinkedIn: www.linkedin.com/company/transcelerate-biopharma-inc-